Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Modern medical innovations continue to transform treatment approaches for chronic conditions, and Ozempic stands at the ...

The Food and Drug Administration allows for licensed compounding pharmacies to make copies of certain drugs in short supply, and that has included semaglutide and tirzepatide, the main ingredients in ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

The company's semaglutide injection—better known by the brand names Ozempic and Wegovy—has become well-known for its weight-loss results and ability to manage diabetes. And while there are several ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical ...

Semaglutide and a similar compound, tirzepatide, had been on the FDA’s shortages list since 2022, and the popularity of the ...

Semaglutide helps regulate blood sugar levels, and works by binding to receptors of the gut hormone Glucagon-like peptide–1 ...